Global Anti-Hypertensive Drug Market Size, Share, Opportunities, And Trends By Drug Class (Diuretics, Beta-Blockers, ACI Inhibitors, Calcium Channel Blockers, Combined Alpha and Beta-Blockers, Others), By Type (Primary Hypertension, Secondary Hypertension), By Sales Channel (Prescription, Over-the-counter (OTC)), And By Geography - Forecasts From 2025 To 2030

Anti-Hypertensive Drug Market Size

The global anti-hypertensive drug market is estimated to grow at a CAGR of 2.88% to reach a market size of US$47.241 billion in 2030 from US$41.082 billion in 2025.  

The global anti-hypertensive drug market is poised to surge at substantial growth over the next five years on account of the growing prevalence of hypertension across the globe due to the unhealthy lifestyles of people. Furthermore, the growing geriatric population is also one of the prime factors anticipated to augment the demand for these drugs, as older adults are considerably more susceptible to high blood pressure than young people. Hypertension is also a major cause of premature deaths worldwide.

The other factors contributing to the prevalence of high blood pressure also include excess smoking, stress, chronic kidney disease, excess alcohol consumption, and obesity.  All these factors play a crucial role in causing high blood pressure in individuals. Thus, the growing number of smokers and alcohol intake, especially among the millennial population, is anticipated to propel the growth opportunities for the market to expand throughout the forecast period and beyond as the prevalence of hypertension is expected to rise due to these factors. Similarly, the continuously growing proportion of the obese population, along with the growing prevalence of obesity among adults, is expected to drive the demand for these drugs during the coming years.

Furthermore, rapid urbanization and globalization are also factors that are deteriorating the conditions of human health. Also, the changing lifestyle of the people, along with the rising stress level, is driving the demand for hypertension drugs. Moreover, an unhealthy lifestyle in terms of eating and sleeping habits of the people also leads to high blood pressure, which is also anticipated to positively impact the anti-hypertensive drugs market growth during the next five years.

Anti-Hypertensive Drug Market Drivers:

• The rising prevalence of hypertension is expected to accelerate the expansion of the global anti-hypertensive drug market.

One of the major factors significantly driving the demand for these drugs is the growing prevalence of hypertension globally. The growing number of smokers, along with the rising proportion of the population with excessive alcohol intake, especially in underdeveloped economies, is boosting the demand for these drugs significantly. According to data from the World Health Organization, there are around 1.13 billion people with hypertension, most of whom live in low and middle-income countries. In addition, the global target of WHO to reduce the prevalence of hypertension by 25% by 2025 is also anticipated to boost the demand for these drugs and add up to the market growth significantly.

Additionally, the consumption of these drugs is considered highly necessary as one of the highly focused public health challenges because hypertension increases the risk of cardiovascular disease. Thus, the drugs for controlling elevated levels of blood pressure reduce the risks of strokes, heart attacks, and also heart failures.

• The growing geriatric population is also anticipated to drive the demand for anti-hypertensive drugs globally.

The growth in the geriatric population around to globe is also considered to be one of the key factors that are anticipated to push the demand for anti-hypertensive drugs during the next five years. There is a significant increase in the aging population, propelling the demand for various drugs as a demographic shift towards an older population is putting a higher burden on various age-associated diseases worldwide. The major factors responsible for the growing aging population include increased life expectancy and declining fertility.

Also, according to the data provided by the United Nations, the number of people aged 60 or above is expected to reach 20805 million by 2050, from only 962.3 in 2017. In addition, older people are expected to be more susceptible to suffering from high blood pressure, which is expected to propel the demand for these drugs throughout the forecast period and beyond. Moreover, there is a significant increase in the proportion of the geriatric population globally.

Anti-Hypertensive Drug Market Geographical Outlook:

• Asia Pacific region to hold considerable shares of the global anti-hypertensive drug market.

Geographically, the global anticoagulants market has been segmented into North America, South America, Europe, the Middle East and Africa, and the Asia Pacific. Based on geography, the global anti-hypertensive drugs market has been segmented into North America, South America, Europe, the Middle East and Africa, and the Asia Pacific. The market in the Asia Pacific region is projected to show notable growth during the next five years on account of the rising prevalence of hypertension in developing countries such as India and China due to the high number of smokers and unhealthy lifestyles of the people. In addition, the growing geriatric population in many countries of the APAC region also supports market growth in the coming years.

Furthermore, hypertension becomes a foremost public health concern for nearly millions of people in North America, caused largely by lifestyle factors such as obesity and lack of exercise. The fact that people have gotten older, especially older persons among them, makes them more susceptible to develop hypertension, the future process is expected to increase demand for these antihypertension drugs.

A developed healthcare system in North America creates the perfect opportunity to expose individuals with hypertensive cases to advanced medical technologies for care. The market growth can also be attributed to the involvement of leading pharmaceutical companies developing or marketing anti-hypertensive drugs in the region. Additionally, the rising consciousness concerning hypertension risks and the existence of new and potent drugs would further propel the North American market.

Anti-Hypertensive Drug Market Key Developments:

• April 2024- The KARDIA-2 Phase 2 Study of Zilebesiran, a medication as adjunctive therapy to standard care antihypertensives, provided positive results in patients with inadequately controlled hypertension. The study was positive because of the clinically significant reduction in ambulatory systolic blood pressure and office systolic blood pressure due to administration of Zilebesiran in a single dose. It also proved the safety and tolerability profile of Zilebesiran when added to standard care antihypertensives.
• March 2024- TRYVIO (aprocitentan), the only U. S. FDA approval for Indonesia, becomes the first and only endothelin receptor antagonist for the treatment of high blood pressure that is not adequately controlled in combination with other antihypertensive agents. TRYVIO is indicated for worsening hypertension in adult patients not adequately controlled with other antihypertensive drugs. It stands as the first oral anti-hypertensive therapy approved for almost 40 years was planned to be available to millions of US patients from the second half of 2024.

Anti-Hypertensive Drug Market Scope:

Report Metric	Details
Anti-Hypertensive Drug Market Size in 2025	US$41.082 billion
Anti-Hypertensive Drug Market Size in 2030	US$47.241 billion
Growth Rate	CAGR of 2.88%
Study Period	2020 to 2030
Historical Data	2020 to 2023
Base Year	2024
Forecast Period	2025 – 2030
Forecast Unit (Value)	USD Billion
Segmentation	Drug Class Type Sales Channel Geography
Geographical Segmentation	North America, South America, Europe, Middle East and Africa, Asia Pacific
List of Major Companies in the Anti-Hypertensive Drug Market	Boehringer Ingelheim International GmbH DAIICHI SANKYO COMPANY, LIMITED Novartis AG Pfizer Inc. Johnson & Johnson
Customization Scope	Free report customization with purchase

 

The Anti-Hypertensive Drug Market is analyzed into the following segments:

• By Drug Class
  • Diuretics
  • Beta-Blockers
  • ACI Inhibitors
  • Calcium Channel Blockers
  • Combined Alpha and Beta-Blockers
  • Others
• By Type
  • Primary Hypertension
  • Secondary Hypertension
• By Sales Channel
  • Prescription
  • Over-the-counter (OTC)
• By Geography
  • North America
    • USA
    • Canada              
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • Israel
    • Others
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Indonesia
    • Taiwan
    • Others

Our Best-Performing Industry Reports:

 

• IgA Nephropathy Disease Treatment Market
• Smart Medical Device Market
• Refurbished Medical Equipment Market

---

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base and Forecast Years Timeline

1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

2.1. Research Design

2.2. Research Process

3. EXECUTIVE SUMMARY

3.1. Key Findings

3.2. Analyst View

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. GLOBAL ANTI-HYPERTENSIVE DRUG MARKET BY DRUG CLASS

5.1. Introduction

5.2. Diuretics

5.3. Beta-Blockers

5.4. ACI Inhibitors

5.5. Calcium Channel Blockers

5.6. Combined Alpha and Beta-Blockers

5.7. Others

6. GLOBAL ANTI-HYPERTENSIVE DRUG MARKET BY TYPE 

6.1. Introduction

6.2. Primary Hypertension

6.3. Secondary Hypertension

7. GLOBAL ANTI-HYPERTENSIVE DRUG MARKET BY SALES CHANNEL 

7.1. Introduction

7.2. Prescription

7.3. Over-the-counter (OTC)

8. GLOBAL ANTI-HYPERTENSIVE DRUG MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. By Drug Class

8.2.2. By Type

8.2.3. By Sales Channel

8.2.4. By Country

8.2.4.1. USA

8.2.4.2. Canada

8.2.4.3. Mexico

8.3. South America

8.3.1. By Drug Class

8.3.2. By Type

8.3.3. By Sales Channel

8.3.4. By Country

8.3.4.1. Brazil

8.3.4.2. Argentina

8.3.4.3. Others

8.4. Europe

8.4.1. By Drug Class

8.4.2. By Type

8.4.3. By Sales Channel

8.4.4. By Country

8.4.4.1. Germany

8.4.4.2. France

8.4.4.3. United Kingdom

8.4.4.4. Spain

8.4.4.5. Others

8.5. Middle East and Africa

8.5.1. By Drug Class

8.5.2. By Type

8.5.3. By Sales Channel

8.5.4. By Country

8.5.4.1. Saudi Arabia

8.5.4.2. Israel

8.5.4.3. Others

8.6. Asia Pacific

8.6.1. By Drug Class

8.6.2. By Type

8.6.3. By Sales Channel

8.6.4. By Country

8.6.4.1. China 

8.6.4.2. Japan

8.6.4.3. South Korea

8.6.4.4. India

8.6.4.5. Indonesia

8.6.4.6. Taiwan

8.6.4.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Boehringer Ingelheim International GmbH

10.2. DAIICHI SANKYO COMPANY, LIMITED

10.3. Novartis AG

10.4. Pfizer Inc.

10.5. Johnson & Johnson

10.6. Merck and Co. Inc.

10.7. Lupin Pharmaceuticals, Inc.

10.8. Sanofi S.A.

10.9. Sun Pharmaceutical Industries Ltd.

10.10. Bristol-Myers Squibb and Company

Boehringer Ingelheim International GmbH

DAIICHI SANKYO COMPANY, LIMITED

Novartis AG

Pfizer Inc.

Johnson & Johnson

Merck and Co. Inc.

Lupin Pharmaceuticals, Inc.

Sanofi S.A.

Sun Pharmaceutical Industries Ltd.

Bristol-Myers Squibb and Company